LU91215I2 - Kepivance (palifermin) - Google Patents

Kepivance (palifermin)

Info

Publication number
LU91215I2
LU91215I2 LU91215C LU91215C LU91215I2 LU 91215 I2 LU91215 I2 LU 91215I2 LU 91215 C LU91215 C LU 91215C LU 91215 C LU91215 C LU 91215C LU 91215 I2 LU91215 I2 LU 91215I2
Authority
LU
Luxembourg
Prior art keywords
polypeptide
mature
fragment
full
length
Prior art date
Application number
LU91215C
Other languages
English (en)
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of LU91215I2 publication Critical patent/LU91215I2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
LU91215C 1993-06-29 2006-01-27 Kepivance (palifermin) LU91215I2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8642793A 1993-06-29 1993-06-29
PCT/US1994/004694 WO1995001434A1 (en) 1993-06-29 1994-04-28 A truncated keratinocyte growth factor (kgf) having increased biological activity

Publications (1)

Publication Number Publication Date
LU91215I2 true LU91215I2 (en) 2006-03-27

Family

ID=22198501

Family Applications (1)

Application Number Title Priority Date Filing Date
LU91215C LU91215I2 (en) 1993-06-29 2006-01-27 Kepivance (palifermin)

Country Status (25)

Country Link
US (7) US5677278A (enExample)
EP (2) EP0706563B1 (enExample)
JP (4) JP3570516B2 (enExample)
KR (1) KR960703433A (enExample)
CN (1) CN1129955A (enExample)
AT (1) ATE278777T1 (enExample)
AU (1) AU681405B2 (enExample)
BG (1) BG100236A (enExample)
BR (1) BR9407035A (enExample)
CA (1) CA2166278A1 (enExample)
CZ (1) CZ343795A3 (enExample)
DE (2) DE69434053T2 (enExample)
DK (1) DK0706563T3 (enExample)
ES (1) ES2227527T3 (enExample)
FI (1) FI956203A7 (enExample)
FR (1) FR06C0004I2 (enExample)
HU (1) HUT73453A (enExample)
LU (1) LU91215I2 (enExample)
NL (1) NL300217I2 (enExample)
NO (1) NO955189D0 (enExample)
NZ (1) NZ266622A (enExample)
PL (1) PL312257A1 (enExample)
PT (1) PT706563E (enExample)
SK (1) SK153295A3 (enExample)
WO (1) WO1995001434A1 (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7026291B1 (en) 1989-01-31 2006-04-11 The United States Of America As Represented By The Department Of Health And Human Services Epithelial cell specific growth factor, keratinocyte growth factor (KGF)
GEP20022681B (en) 1989-01-31 2002-04-25 Aaronson Us Stuart A Protein KFG, Antibodies, Pharmaceutical Composition, Their Use, recombinant DNA, Cell, Method for Discoveries and Production of Proteins, Method for Stimulation of Epithelial Cells Growth
US5814605A (en) * 1993-03-26 1998-09-29 Amgen Inc. Therapeutic uses of keratinocyte growth factor
US7084119B2 (en) * 1993-06-29 2006-08-01 Chiron Corporation Truncated keratinocyte growth factor (KGF) having increased biological activity
BR9407035A (pt) * 1993-06-29 1996-03-12 Chiron Corp Fragmento de fator de crescimento de queratinócitos conjugado composição terapêutica molécula de DNA vetor de expressão célula hospedeira processo para produzir fragmento de fator de crescimento de queratinócitos processo para cicatrização de ferimento e processo de tratamento de doença hiperproliferativa da epiderme
SI0785949T1 (en) * 1994-10-13 2003-08-31 Amgen Inc. Method for purifying keratinocyte growth factors
US6008328A (en) * 1994-10-13 1999-12-28 Amgen Inc. Method for purifying keratinocyte growth factors
AU745815B2 (en) * 1994-10-13 2002-04-11 Biovitrum Ab (Publ) Analogs of keratinocyte growth factor, nucleic acids encoding such analogs, processes of making and methods of using
CN1168678A (zh) * 1994-10-13 1997-12-24 安姆根有限公司 用kgf治疗糖尿病的方法
US6077692A (en) 1995-02-14 2000-06-20 Human Genome Sciences, Inc. Keratinocyte growth factor-2
US6693077B1 (en) 1995-02-14 2004-02-17 Human Genome Sciences, Inc. Keratinocyte growth factor-2
US7232667B2 (en) 1995-02-14 2007-06-19 Human Genome Sciences, Inc. Keratinocyte growth factor-2 polynucleotides
ES2293137T3 (es) * 1995-10-11 2008-03-16 Novartis Vaccines And Diagnostics, Inc. Combinacion de pdgf, kgf,igf e igfbp para curacion de heridas.
US6692961B1 (en) 1996-10-11 2004-02-17 Invitrogen Corporation Defined systems for epithelial cell culture and use thereof
DK0935652T3 (da) * 1996-10-15 2004-07-26 Amgen Inc Keratinocyt vækstfaktor-2 produkter
US6743422B1 (en) 1996-10-15 2004-06-01 Amgen, Inc. Keratinocyte growth factor-2 products
US20030144202A1 (en) * 1996-10-15 2003-07-31 Amgen Inc. Uses of keratinocyte growth factor-2
EP1473366A1 (en) * 1996-10-15 2004-11-03 Amgen Inc. Keratinocyte growth factor-2 products
JP2002513294A (ja) * 1997-06-19 2002-05-08 ジェネティックス・インスチチュート・インコーポレーテッド 分泌蛋白およびそれらをコードするポリヌクレオチド
US20080233086A1 (en) * 1997-09-05 2008-09-25 Canbiocin Inc. Expression Vectors for Treating Bacterial Infections
US6869927B1 (en) 1997-12-22 2005-03-22 Human Genome Sciences, Inc. Keratinocyte growth factor-2 formulations
KR20010033484A (ko) 1997-12-22 2001-04-25 휴먼 게놈 사이언시즈, 인크. 각질세포 성장 인자-2 제제
US6599879B1 (en) * 1998-02-13 2003-07-29 Human Genome Sciences, Inc. Therapeutic uses of keratinocyte growth factor-2
DE19934510B4 (de) * 1999-07-22 2009-04-16 Vermicon Ag Verfahren zum Nachweis von Mikroorganismen
WO2001027301A2 (en) 1999-10-15 2001-04-19 The Rockefeller University System for rapid generation of recombinant baculovirus-based expression vectors for silkworm larvae
DE10024334B4 (de) * 2000-05-17 2006-06-01 Medigene Ag Verfahren zum Einbringen von Nukleinsäure in eine Zelle (Transfektion) mittels Calciumphosphat
AU2002236477A1 (en) 2000-11-21 2002-06-03 The Texas A & M University System Fgf-affinity chromatography
EP1357931A2 (en) * 2001-01-08 2003-11-05 Human Genome Sciences, Inc. Keratinocyte growth factor-2
AU2002256624B2 (en) 2001-02-19 2007-12-06 Merck Patent Gmbh Method for identification of T-cell epitopes and use for preparing molecules with reduced immunogenicity
JP2005500390A (ja) * 2001-08-21 2005-01-06 カイロン コーポレイション Ｋｇｆポリペプチド組成物
US7202066B2 (en) * 2002-01-29 2007-04-10 Carrington Laboratories, Inc. Combination of a growth factor and a protease enzyme
GB0426394D0 (en) 2004-12-01 2005-01-05 Health Prot Agency Fusion proteins
CA2589889C (en) * 2004-12-15 2013-07-30 Amgen Inc. Therapeutic formulations of keratinocyte growth factor
US20060183712A1 (en) * 2005-02-17 2006-08-17 The Texas A&M University System Affinity purified heparin/heparan sulfate for controlling the biological activity of the FGF receptor
AU2006335256B2 (en) * 2005-11-22 2012-10-18 Novartis Vaccines And Diagnostics, Inc. Norovirus and sapovirus antigens
GB0611405D0 (en) 2006-06-09 2006-07-19 Univ Belfast FKBP-L: A novel inhibitor of angiogenesis
WO2008005533A2 (en) * 2006-07-06 2008-01-10 Aaron Thomas Tabor Compositions and methods for genetic modification of cells having cosmetic function to enhance cosmetic appearance
KR101021197B1 (ko) * 2008-04-11 2011-03-11 (주)케어젠 성장인자―미미킹 펩타이드 및 그의 용도
US9132202B2 (en) 2009-07-17 2015-09-15 Aaron T. Tabor Compositions and methods for genetic modification of cells having cosmetic function to enhance cosmetic appearance
MX2016005614A (es) 2013-11-01 2016-12-09 Spherium Biomed S L Cuerpos de inclusion para el suministro transdermico de agentes terapeuticos y cosmeticos.
JP2024532086A (ja) 2021-08-30 2024-09-05 ユニケム ラボラトリーズ リミテッド 炎症性疾患の処置のためのタンパク質組成物
KR102691028B1 (ko) * 2021-11-15 2024-08-05 (주)피앤피바이오팜 안정성이 증가된 인간 각질세포 성장인자1 변이체 및 이의 용도

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP20022681B (en) * 1989-01-31 2002-04-25 Aaronson Us Stuart A Protein KFG, Antibodies, Pharmaceutical Composition, Their Use, recombinant DNA, Cell, Method for Discoveries and Production of Proteins, Method for Stimulation of Epithelial Cells Growth
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
US5814605A (en) 1993-03-26 1998-09-29 Amgen Inc. Therapeutic uses of keratinocyte growth factor
BR9407035A (pt) 1993-06-29 1996-03-12 Chiron Corp Fragmento de fator de crescimento de queratinócitos conjugado composição terapêutica molécula de DNA vetor de expressão célula hospedeira processo para produzir fragmento de fator de crescimento de queratinócitos processo para cicatrização de ferimento e processo de tratamento de doença hiperproliferativa da epiderme
MX9702665A (es) 1994-10-13 1997-07-31 Amgen Inc Analogos del factor de crecimiento de queratinocitos.
CN1168678A (zh) 1994-10-13 1997-12-24 安姆根有限公司 用kgf治疗糖尿病的方法

Also Published As

Publication number Publication date
US6074848A (en) 2000-06-13
NO955189L (no) 1995-12-20
DK0706563T3 (da) 2005-01-31
JP3570516B2 (ja) 2004-09-29
JP2009062396A (ja) 2009-03-26
NL300217I2 (nl) 2006-05-01
US5677278A (en) 1997-10-14
NL300217I1 (nl) 2006-04-03
FI956203A7 (fi) 1996-02-07
JP2006075173A (ja) 2006-03-23
EP1493812A2 (en) 2005-01-05
PL312257A1 (en) 1996-04-01
CA2166278A1 (en) 1995-01-12
US5863767A (en) 1999-01-26
EP0706563B1 (en) 2004-10-06
DE122006000005I1 (de) 2006-08-10
US6677301B1 (en) 2004-01-13
DE122006000005I2 (de) 2006-11-23
PT706563E (pt) 2005-01-31
CZ343795A3 (en) 1996-07-17
BR9407035A (pt) 1996-03-12
KR960703433A (ko) 1996-08-17
FR06C0004I1 (enExample) 2006-03-10
FR06C0004I2 (fr) 2006-12-29
AU681405B2 (en) 1997-08-28
US5843883A (en) 1998-12-01
JPH09500267A (ja) 1997-01-14
ES2227527T3 (es) 2005-04-01
US20090093400A1 (en) 2009-04-09
AU6820894A (en) 1995-01-24
EP1493812A3 (en) 2006-02-08
BG100236A (en) 1996-07-31
JP2004166709A (ja) 2004-06-17
NZ266622A (en) 1997-10-24
CN1129955A (zh) 1996-08-28
EP0706563A1 (en) 1996-04-17
WO1995001434A1 (en) 1995-01-12
US5773586A (en) 1998-06-30
DE69434053T2 (de) 2006-02-23
SK153295A3 (en) 1996-11-06
DE69434053D1 (de) 2005-01-20
HU9503857D0 (en) 1996-02-28
JP4662569B2 (ja) 2011-03-30
FI956203A0 (fi) 1995-12-22
HUT73453A (en) 1996-08-28
NO955189D0 (no) 1995-12-20
ATE278777T1 (de) 2004-10-15

Similar Documents

Publication Publication Date Title
HU9503857D0 (en) A truncated keratinocyte growth factor /kgf/ having increased biological activity
CA2168011A1 (en) Hybrid toxin
GB8909919D0 (en) Small polypeptides
DE4391636T1 (de) Betriebsventilanordnung mit Druckausgleichsventil
DE122007000030I1 (de) Für menschliches Papillomavirus stamm 18 kodierende DNS
DE69225597D1 (de) Peptide mit einer lanthionin-brücke
BR9002253A (pt) Valvula reguladora com compensacao de queda
DE69013042D1 (de) Ventil mit eingekapselten Balgen für Gas von höchster Reinheit.
AU4569285A (en) Nematode control by recombinant microorganisms
SE8801723D0 (sv) Fibronectin binding protein as well as its preparation
EP0254272A3 (en) The use of probucol for preventing and treating heart diseases
DE3861802D1 (de) Regelungsventil fuer gas.
EP0206329A3 (en) Sprung floor
IT219518Z2 (it) Leva di comando particolarmente per l'azionamento di gruppi valvolari
EP0351831A3 (en) Improved polyester compositions
PH23917A (en) Substituted 1,2,3-thiadiazole-4-thiolates
IT233173Y1 (it) Attuatore lineare, particolarmente per l'azionamento di componenti di arredamento o simili, a ridotta rumorosita'
CS218388A1 (en) Panel for walking beam furnace's buffer
EP0284510A3 (en) N-[N alpha-(1(S)-carboxy-3-cyclohexyl-propyl)-1-lysyl] N-cyclopentylglycine as antihypertensives
BR6902552U (pt) Conjunto cinematico de controle de pressao de ar
RO104008B1 (en) Control of adaptive admission at thermal engines
RO104010B1 (en) Control of adaptive admission at thermal engines
CS337689A2 (en) Regulator's operating mode control connection
ITVR920043A1 (it) Manopola di comando